The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).
David P. Ryan
No relevant relationships to disclose
Shantan G. Reddy
No relevant relationships to disclose
Nathan Bahary
No relevant relationships to disclose
Hope Elizabeth Uronis
No relevant relationships to disclose
Darren Sigal
No relevant relationships to disclose
Allen Lee Cohn
No relevant relationships to disclose
William R. Schelman
No relevant relationships to disclose
Joe Stephenson
No relevant relationships to disclose
Clarence Eng
No relevant relationships to disclose
Mitesh J. Borad
No relevant relationships to disclose